Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of ...

Luxury fashion house LVMH has reclaimed its title as Europe’s most valuable company from Novo Nordisk, as early signs of a luxury comeback coincided with fresh struggles for the Danish Ozempic ...

Novo Nordisk (NVO) shares are surging by nearly 11% in Friday's pre-market trading after releasing positive early trial results for the company's injectable GLP-1 weight-loss drug, amycretin.

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 11 unusual trades. Delving into the details, we found 72% of ...